REAL-WORLD EXPERIENCE WITH PCSK9 INHIBITORS PROTOCOL FOR HYPERCHOLESTEROLEMIA

M.I. SÁEZ RODRÍGUEZ1, J.J. ARENAS VILLAFRANCA1, B. MONTERO SALGADO1, P.A. CHINCHURRETA CAPOTE2, B. TORTAJADA GOITIA1.
1COSTA DEL SOL HOSPITAL, PHARMACY, MARBELLA, SPAIN.
2COSTA DEL SOL HOSPITAL, CARDIOLOGY, MARBELLA, SPAIN.

BACKGROUND AND OBJECTIVES

CSK9 inhibitors (PCSK9i) are drugs that reduce low density lipoprotein (LDL) levels. Due to their high cost and restrictive indications, a Drug Use Evaluation (DUE) was performed.

AIM AND OBJECTIVES

Evaluate a protocol for PCSK9i use and patients’ follow-up developed in our center.

MATERIAL AND METHODS

All patients with PCSK9i were included in the study.

Variables:
- Sex, age
- Last appointment with the doctor
- LDL-levels before treatment (LDL-1)
- LDL-levels after one month (LDL-2)
- In patients with more than one year treatment, date and results of the last LDL analytic (LDL-3).

A descriptive analysis was performed using measures of central tendency, dispersion and position for quantitative variables, and frequency distribution for qualitative variables.

RESULTS

161 patients were included
- 67.7% male
- 23.3% female
- Medium age was 60±8,7 years
- Follow up ranged from 2 months to 5 years

Treatment regimens
- Evolocumab 140 mg / 2 weeks: 30 (18,6%)
- Alirocumab 75 mg / 2 weeks: 96 (59,6%)
- Alirocumab 150 mg / 2 weeks: 35 (21,7%)

17 patients (10,55%) didn’t have an analytic in the last year, and 10 patients (6,21%) hadn’t had an appointment with their doctor in more than a year.

38 patients (23,6%) had LDL-levels over the objective.
According to guidelines and protocol, these patients were referred to the physician for revision

Medium LDL-levels improvement after one month was 71,7±41,2 mg/dl.

<table>
<thead>
<tr>
<th></th>
<th>Minimum (mg/dl)</th>
<th>Maximum (mg/dl)</th>
<th>Medium (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDL-1</td>
<td></td>
<td>344</td>
<td>132,5 ± 47,3</td>
</tr>
<tr>
<td>LDL-2</td>
<td>8</td>
<td>188</td>
<td>60,49 ± 34,04</td>
</tr>
<tr>
<td>LDL-3</td>
<td>7</td>
<td>160</td>
<td>61,59 ± 33,96</td>
</tr>
</tbody>
</table>

CONCLUSION AND RELEVANCE

Although some patients don’t reach the desired outcome and/or their monitoring may be improved, our data shows that PCSK9i cause a great reduction of LDL levels that is maintained in time.

Contact data: MI Sáez. maissaro@hcs.es

4CPS-119